What hormone replacement therapy regimen is recommended for a menopausal woman with an intact uterus who seeks relief of hot flashes?

Hormone Replacement Therapy for Hot Flashes in Women with Intact Uterus

For a menopausal woman with an intact uterus seeking relief from hot flashes, prescribe combined estrogen-progestogen therapy (EPT), which reduces vasomotor symptoms by approximately 75% and remains the most effective treatment available 1, 2.

Essential Requirement: Progestogen Protection

Women with an intact uterus must receive a progestogen alongside estrogen to prevent endometrial hyperplasia and cancer 1, 3. Never prescribe estrogen alone in this population—this is a critical safety requirement.

Recommended Regimens

First-Line Options:

• Oral or transdermal estrogen + progestogen (continuous combined or cyclic regimen)

  • Both routes have similar efficacy for vasomotor symptoms 2
  • Transdermal may have lower thrombotic risk, though this is based on observational data

• Conjugated equine estrogens (CEE) + bazedoxifene (where available)

  • This combination is specifically suggested for women with a uterus 1
  • Bazedoxifene (a SERM) provides endometrial protection without traditional progestogen side effects 3, 4
  • Low-dose CEE/bazedoxifene shows no increased breast cancer risk (0.25%/year vs 0.23%/year with placebo) 2

• Tibolone (in countries where available)

  • Suggested as an alternative to standard MHT 1
  • Do not combine with other MHT forms 1
  • Contraindicated in women with breast cancer history 1

Dosing Strategy

Use the lowest effective dose for the shortest duration consistent with treatment goals 1, 4. Start with standard doses and titrate down once symptoms are controlled.

Timing Matters for Safety

The benefit-risk ratio is most favorable when:

• Age <60 years, OR
• Within 10 years of menopause onset 5, 6

Women initiating therapy >10 years from menopause or age >60 face greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia 5.

Key Risks to Discuss

Combined EPT carries approximately 1 excess event per 1,000 person-years for:

• Stroke
• Venous thromboembolism
• Breast cancer (with CEE + MPA specifically) 2

Breast cancer risk increases with EPT use beyond 3-5 years 4. Emphasize adherence to age-appropriate breast cancer screening 1.

Ongoing Management

• Revisit the decision to continue MHT at least annually 1
• Evaluate any unscheduled bleeding promptly to rule out endometrial pathology 1
• When discontinuing, use shared decision-making regarding gradual taper vs. abrupt cessation 1

Common Pitfall to Avoid

The most dangerous error is prescribing unopposed estrogen to a woman with an intact uterus. This dramatically increases endometrial cancer risk. Always verify uterine status before prescribing and ensure progestogen protection is included 3, 4.